Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + everolimus + lenvatinib
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is an investigational combination therapy consisting of three small molecule inhibitors: trametinib, everolimus, and lenvatinib. Trametinib is a selective inhibitor of MEK1 and MEK2, components of the MAPK/ERK pathway; everolimus is an mTOR inhibitor targeting the PI3K/AKT/mTOR signaling pathway; and lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. This triple combination aims to simultaneously inhibit tumor cell proliferation, angiogenesis, and survival pathways. It is currently being studied in clinical trials for recurrent or refractory advanced solid tumors[1][3][4][8].
- Brand names
- Mekinist (trametinib)Afinitor (everolimus)Lenvima (lenvatinib)Kisplyx (lenvatinib)
- Other names
- trametinib + everolimus + lenvatinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)mTOR (Mammalian target of rapamycin kinase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on trametinib + everolimus + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + everolimus + lenvatinib.